View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 7, 2011

Pfizer Reports Positive Results of Lyrica

Pfizer has announced the top-line results from a Phase III study of Lyrica (pregabalin) as a treatment of fibromyalgia. The 16-week, randomised, double-blind, multicentre and placebo-controlled A0081208 study enrolled 501 subjects. The drug demonstrated a reduction in endpoint mean pain

By cms admin

Pfizer has announced the top-line results from a Phase III study of Lyrica (pregabalin) as a treatment of fibromyalgia.

The 16-week, randomised, double-blind, multicentre and placebo-controlled A0081208 study enrolled 501 subjects. The drug demonstrated a reduction in endpoint mean pain score compared to a placebo.

The drug-related adverse events include drowsiness, dizziness, weight increase, constipation, oedema peripheral and blurred vision.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology